Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic HematopoiesisMasters of Survival and Clonality?.
Zaborsky, N, Gassner, FJ, Asslaber, D, Reinthaler, P, Denk, U, Flenady, S, Hofbauer, JP, Danner, B, Rebhandl, S, Harrer, A, Geisberger, R, Greil, R, Egle, A. Oncotarget. 2016.
Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL-Letter.
Rinnerthaler, G, Hackl, H, Gampenrieder, SP, Hamacher, F, Hufnagl, C, Hauser-Kronberger, C, Zehentmayr, F, Fastner, G, Sedlmayer, F, Mlineritsch, B, Greil, R. Int J Mol Sci. 2016, 17(2).
Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis -Masters of Survival and Clonality?.
Pleyer, L, Valent, P, Greil, R. INT J MOL SCI. 2016, 17(7): 1009.
View this publication in the PUBMED databaseAn international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide?+?dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM).
Leleu, X, Terpos, E, Sanz, RG, Cooney, J, O“Gorman, P, Minarik, J, Greil, R, Williams, C, Gray, D, Szabo, Z. AM J HEMATOL. 2016, 91(8): 806-811.
View this publication in the PUBMED databasePanitumumab-Associated Encephalopathy after Accidental Intra-arterial Application through Dislocated Central Venous Access Device.
Pikija, S, Pilz, G, Gschwandtner, G, Rösler, C, Schlick, K, Greil, R, Sellner, J. Front Neurol. 2016, 7:196.
BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia.
Haerzschel, A, Catusse, J, Hutterer, E, Paunovic, M, Zirlik, K, Eibel, H, Krenn, PW, Hartmann, TN, Burger, M. Ann Hematol. 2016, 95(12):197-1988.
Assessment of Pharmacokinetic Interaction Between Capecitabine and Cetuximab in Metastatic Colorectal Cancer Patients.
Steiner, M, Harrer, A, Himly, M. Front Pharmacol. 2016, 7:171.
CD44: More than a mere stem cell marker.
Morath, I, Hartmann, TN, Orian-Rousseau, V. Int J Biochem Cell Biol. 2016.
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
Greil, R, ObrtlГkovГЎ, P, Smolej, L, KozГЎk, T, Steurer, M, Andel, J, Burgstaller, S, MikuЕЎkovГЎ, E, Gercheva, L, NГ¶sslinger, T, PapajГk, T, LadickГЎ, M, Girschikofsky, M, HrubiЕЎko, M, JГ¤ger, U, Fridrik, M, Pecherstorfer, M, KrГЎlikovГЎ, E, Burcoveanu, C, Spasov, E, Petzer, A, Mihaylov, G, Raynov, J, Oexle, H, Zabernigg, A, FlochovГЎ, E, PalГЎЕЎthy, S, StehlГkovГЎ, O, Doubek, M, Altenhofer, P, Pleyer, L, Melchardt, T, Klingler, A, Mayer, J, Egle, A. Lancet Haematol. 2016, 3(7):e317-e329.
Epidermal-specific deletion of CD44 reveals a function in keratinocytes in response to mechanical stress.
Shatirishvili, M, Burk, AS, Franz, CM, Pace, G, Kastilan, T, Breuhahn, K, Hinterseer, E, Dierich, A, Bakiri, L, Wagner, EF, Ponta, H, Hartmann, TN, Tanaka, M, Orian-Rousseau, V. Cell Death Dis. 2016, 7(11):e2461.
